Timing of dual antiplatelet therapy in acute coronary syndrome: a problem of coronary artery bypass grafting accessibility for patients
https://doi.org/10.15829/1560-4071-2020-3812
Abstract
The feasibility of dual antiplatelet therapy as early as possible in patients with ST-segment elevation acute coronary syndrome, where percutaneous coronary intervention is recommended, has been proven: it improves treatment outcomes by reducing the risk of adverse ischemic events, including stent thrombosis and myocardial infarction.
This article provides a detailed analysis of the evidence data and current recommendations on the validity and timing of dual antiplatelet therapy for acute coronary syndrome. The emphasis is made on the controversy regarding the early dual antiplatelet therapy in non-ST-segment elevation acute coronary syndrome. The rationale for using dual antiplatelet therapy only after coronary angiography and determining the revascularization strategy is described, which should increase the accessibility of coronary artery bypass graft surgery for patients.
About the Authors
T. S. Golovina
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Kemerovo
Russian Federation
Kemerovo
Yu. N. Neverova
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Kemerovo
Russian Federation
Kemerovo
R. S. Tarasov
Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Kemerovo
Russian Federation
Kemerovo
References
1. Valgimigli M, Bueno H, Byrne RA, et al. Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Rev Esp Cardiol (Engl Ed). 2018;71(1):42. doi:10.1016/j.rec.2017.11.020.
2. 2018 ESC/EACTS guidelines on myocardial revascularization. Russian Journal of Cardiology. 2019;(8):151-226. (In Russ.) doi:10.15829/1560-4071-2019-8-151-226.
3. Stojkovic S, Nossent А, Haller P. MicroRNAs as Regulators and Biomarkers of Platelet Function and Activity in Coronary Artery Disease. Thromb Haemost. 2019;19(10):1563-72. doi:10.1055/s-0039-1693702.
4. Patti G, Pasceri V, Mangiacapra F, et al. Efficacy of Clopidogrel Reloading in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention During Chronic Clopidogrel Therapy (From the Antiplatelet Therapy for Reduction of MYocardial Damage During Angioplasty [ARMYDA-8 RELOAD-ACS] Trial). Am J Cardiol. 2013;112(2):162-8. doi:10.1016/j.amjcard.2013.03.008.
5. von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation. 2005;112:2946-50. doi:10.1161/CIRCULATIONAHA.105.559088.
6. Schulz S, Angiolillo DJ, Antoniucci D. Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trial. J Cardiovasc Transl Res. 2014;7(1):91-100. doi:10.1007/s12265-013-9527-3.
7. Schulz S, Mehilli J, Ndrepepa G. Influence of Abciximab on Evolution of Left Ventricular Function in Patients With non-ST-segment Elevation Acute Coronary Syndromes Undergoing PCI After Clopidogrel Pretreatment: Lessons From the ISAR-REACT 2 Trial. Clin Res Cardiol. 2011;100(8):691-9. doi:10.1007/s00392-011-0299-y.
8. Kastrati A, Neumann FJ, Schulz S, et al. ISAR-REACT Trial Investigators. Abciximab and heparin versus bivalirudin for nonST-elevation myocardial infarction. N Engl J Med. 2011;365:1980-9. doi:10.1056/NEJMoa1109596.
9. Wadowski P, Eichelberger В, Kopp СW. Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy. J Cardiovasc Transl Res. 2017;10(4):359-67. doi:10.1007/s12265-017-9746-0.
10. Nishikawa M, Takeda Y, Isomura N. Association Between High Platelet Reactivity Following Dual Antiplatelet Therapy and Ischemic Events in Japanese Patients With Coronary Artery Disease Undergoing Stent Implantation. J Atheroscler Thromb. 2020;27(1):13-24. doi:10.5551/jat.48934.
11. Motovska Z, Hlinomaz O, Kala P. 1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor. J Am Coll Cardiol. 2018;71(4):371-81. doi:10.1016/j.jacc.2017.11.008.
12. Lindholm D, Varenhorst C, Cannon CP. Ticagrelor vs. clopidogrel in patients with nonST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J. 2014;35(31):2083-93. doi:10.1093/eurheartj/ehu160.
13. Sibbing D, Kastrati A, Berge PB. Pre-treatment with P2Y 12 inhibitors in ACS patients: who, when, why, and which agent? Eur Heart J. 2016;37,16:1284-95, doi:10.1093/eurheartj/ehv717.
14. Bittl J, Baber U, Bradley S, Wijeysundera D. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):1116-39. doi:10.1016/j.jacc.2016.03.512.
15. Reddy S, Mathew M, Patel N. Analyzing the Efficacy and Cost-effectiveness of Antiplatelet Therapy in Unstable Angina/Non-ST Elevation Myocardial Infarction: A Decision Analysis. Cureus. 2019;11(8):e5321. doi:10.7759/cureus.5321.
16. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC / EACTS guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541-619.
17. Motovska Z., Kala P. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries. Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001.
18. Udell JA, Braunwald E, Antman EM. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38). JACC Cardiovasc Interv. 2014;7(6):604-12. doi:10.1016/j.jcin.2014.01.160.
19. Silvain J, Rakowski T, Lattuca B, Liu Z. Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non-ST-Segment Am Coll Cardiol. 2019 Mar 5;73(8):906-14. doi:10.1016/j.jacc.2018.11.055.
20. Montalescot G, Silvain J, Lassen JF, Bolognese L. ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371:1016-27. doi:10.1056/NEJMoa1407024.
21. Zeymer U, Montalescot G, Ardissino D, Bolognese L. Optimal timing of initiation of oral P2Y 12 -receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial. Eur Heart J Acute Cardiovasc Care. 2016;5(3):282-8. doi:10.1177/2048872615584076.
22. Vaduganathan M, Harrington RA, Stone GW. Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. Euro Intervention. 2018;13(15):e1841-e1849. doi:10.4244/EIJ-D-17-00723.
23. Bhatt DL, Stone GW, Mahaffey KW, et al. CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med.2013;368:1303-13. doi:10.1056/NEJMoa1300815.
24. Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315. doi:10.1093/eurheartj/ehv320.
25. Alfredsson J, Neely B, Neely ML. Predicting the Risk of Bleeding During Dual Antiplatelet Therapy After Acute Coronary Syndromes. Heart. 2017;103(15):1168-76. doi:10.1136/heartjnl-2016-310090.
26. McCreight M.S., Lambert-Kerzner A., O’Donnell C.I. et al. Improving anti-platelet therapy adherence in the Veterans Health Administration: A randomized multi-site hybrid effectiveness-implementation study protocol. Contemp Clin Trials. 2019;77:104-110. doi:10.1016/j.cct.2018.12.005.
Review
For citations:
Golovina T.S., Neverova Yu.N., Tarasov R.S. Timing of dual antiplatelet therapy in acute coronary syndrome: a problem of coronary artery bypass grafting accessibility for patients. Russian Journal of Cardiology. 2020;25(8):3812. (In Russ.) https://doi.org/10.15829/1560-4071-2020-3812
Views:
977
Email this article 